Copyright
©2010 Baishideng.
World J Gastroenterol. Jun 7, 2010; 16(21): 2638-2647
Published online Jun 7, 2010. doi: 10.3748/wjg.v16.i21.2638
Published online Jun 7, 2010. doi: 10.3748/wjg.v16.i21.2638
Figure 1 Flow of participants through the study.
Figure 2 Change in mean serum malondialdehyde (MDA) (A) and serum 4-hydroxyalkenals (B) levels during the treatment period.
Error bars indicate SE. P value for the comparison of the Viusid and the control group at 24 wk. A comparative analysis was performed using Wilcoxon rank-sum test.
Figure 3 Change in mean serum levels of TNF-α (A), IFN-γ (B), IL-1α (C) and serum IL-10 (D) during the treatment period.
Error bars indicate SE. P values for the comparison of the Viusid and the control group at 24 wk. A comparative analysis was performed using Wilcoxon rank-sum test. TNF-α: Tumor necrosis factor-α; IFN-γ: Interferon-γ; IL-1α: Interleukin-1α; IL-10: Interleukin-10.
- Citation: Gomez EV, Perez YM, Sanchez HV, Forment GR, Soler EA, Bertot LC, Garcia AY, del Rosario Abreu Vazquez M, Fabian LG. Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C. World J Gastroenterol 2010; 16(21): 2638-2647
- URL: https://www.wjgnet.com/1007-9327/full/v16/i21/2638.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i21.2638